



## **Retrophin to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series**

September 14, 2016

SAN DIEGO, Sept. 14, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Alvin Shih, M.D., executive vice president and head of research & development, will present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series in New York City on Wednesday, September 28, 2016 at 11:05 a.m. ET.

A live webcast of the presentation will be available at <http://ir.retrophin.com/events.cfm> and an archived replay will be accessible for up to 90 days.

### **About Retrophin**

Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products Thiola<sup>®</sup>, Cholbam<sup>®</sup> and Chenodal<sup>®</sup>.

[Retrophin.com](http://Retrophin.com)

Contacts:

(Investors)

Chris Cline, CFA

Senior Director, Investor Relations

646-564-3680

[IR@retrophin.com](mailto:IR@retrophin.com)

The Retrophin logo consists of the word "Retrophin" in a bold, sans-serif font. The letter "R" is significantly larger than the other letters and is enclosed within a rectangular border.

Source: Retrophin, Inc.

News Provided by Acquire Media